K. Hartigan-Go

发表

The politics of Covid-19 vaccine confidence

H. Larson, M. Sabahelzain, K. Hartigan-Go, 2021, Current Opinion in Immunology.

Challenges of Drug Risk Communications in the Philippines

K. Hartigan-Go, 2012, Drug Safety.

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS

Philippe Duclos, Brigitte Autran, Stephen Evans, 2009, Expert review of vaccines.

Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

R. Campbell, F. Kamali, G. Ford, 1995, British heart journal.

Empowering Consumers as Contributors for Health Product Safety: Lessons from the Philippines

K. Hartigan-Go, 2015, Drug Safety.

Stereoselective cardiotoxic effects of terodiline

K. Hartigan-Go, A. Daly, D. Bateman, 1996, Clinical pharmacology and therapeutics.

Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery

M. Lindquist, A. Bate, E. V. van Puijenbroek, 2017, Drug Safety.

Public policy (not the coronavirus) should shape what endemic means

K. Hartigan-Go, A. Brillantes, R. Mendoza, 2022, Journal of global health.

Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence

G. Ford, K. Hartigan-Go, S. H. Thomas, 1996, British journal of clinical pharmacology.

A multinational Delphi consensus to end the COVID-19 public health threat

Manfred S. Green, Bary S. R. Pradelski, LeAnne K. Robinson, 2022, Nature.

COVID-19 Vaccine Hesitancy in ASEAN: Insights from a Multi-wave Survey Database from July 2020 to March 2021

K. Hartigan-Go, R. Mendoza, M. Ong, 2021, Acta Medica Philippina.

Novel vaccine safety issues and areas that would benefit from further research

J. Tate, Peter G. Smith, U. Parashar, 2021, BMJ global health.

Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.

K. Hartigan-Go, D. Barceloux, M. Mcguigan, 1997, Journal of toxicology. Clinical toxicology.

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Robert T. Chen, N. Andrews, K. Hartigan-Go, 2016, Vaccine.

Implementation strategies for the first licensed dengue vaccine: A meeting report.

R. Peeling, D. Gubler, A. Wilder-Smith, 2021, Vaccine.

Redtide in the Philippines

K. Hartigan-Go, D. Bateman, D. Bateman, 1994, Human & experimental toxicology.

Concentration‐related pharmacodynamic effects of thioridazine and its metabolites in humans

K. Hartigan-Go, S. Thomas, G. Nyberg, 1996, Clinical pharmacology and therapeutics.

Consumption of barracuda in the Caribbean Sea linked to ciguatera fish poisoning among Filipino seafarers

K. Hartigan-Go, V. C. de los Reyes, M. N. Sucaldito, 2018, Western Pacific surveillance and response journal : WPSAR.

Epidemic hysteria following the National School Deworming Day, Zamboanga Peninsula, Philippines, 2015

K. Hartigan-Go, V. Belizario, R. Magpantay, 2018, Western Pacific surveillance and response journal : WPSAR.

Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness

H. Larson, K. Hartigan-Go, A. de Figueiredo, 2018, Human vaccines & immunotherapeutics.

Vaccination Programs: Economic and Leadership Considerations.

K. Hartigan-Go, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background.

K. Hartigan-Go, 2002, Toxicology.

Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum

M. Lindquist, A. Bate, I. Edwards, 2014, Drug Safety.

Developing an immunization safety surveillance system in the Philippines.

K. Hartigan-Go, M. C. Roces, O. Mansoor, 2000, Bulletin of the World Health Organization.

The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance

I. Edwards, P. Mol, P. Bahri, 2015, Drug Safety.

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

W. Gaissmaier, J. Aronson, G. Trifirò, 2023, Drug Safety.

Challenges of drug risk communications in the Philippines.

K. Hartigan-Go, 2012, Drug Safety.

Regarding response by Dans et. al. to our article, “Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness.”

H. Larson, K. Hartigan-Go, A. de Figueiredo, 2019, Human Vaccines & Immunotherapeutics.

From Signals to Policies: Academic and Regulatory Perspectives in the Philippines

K. Hartigan-Go, 1999 .

Working Methods for the Adverse Drug Reaction Monitoring Program in the Philippines

K. Hartigan-Go, 1998 .

Inclusion of therapeutic failures as adverse drug reactions

K. Hartigan-Go, J. Wong, 2000 .